The relationship between FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in metastatic colorectal cancer has been investigated with controversial results. However, in line with preclinical studies, the mechanism of antibody-dependent cellular cytotoxicity may be more relevant in the presence of micrometastatic disease. We found that, in a prospective series of locally advanced rectal cancer patients, carriers of 131R and 158F alleles had an increased clinical benefit from cetuximab and this effect appeared to be independent of RAS. These results suggest the hypothesis of a dual mechanism of action of cetuximab (i.e. inhibition of EGFR downstream signalling pathways prevalent for macroscopic disease and ADCC prevalent for microscopic foci of disease) and may trigger further research into the role of the immune-mediated effects of cetuximab and other monoclonal antibodies in the adjuvant setting. Conclusion: This is the first study investigating FcγRIIa and FcγRIIIa polymorphisms in early stage colorectal cancer patients treated with cetuximab. We showed an increased clinical benefit from cetuximab in the presence of 131R and 158F alleles.
Introduction
Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of the epidermal growth factor receptor (EGFR) 1 . Its antitumour activity is largely secondary to the competitive inhibition of EGFR-ligand interactions, prevention of receptor dimerization and autophosphorylation, and blockage of EGFR signaling through the MAPK and PI3K-AKT-mTOR pathways. Following binding to EGFR, cetuximab exerts an inhibitory effect on tumour proliferation, survival, motility, invasion and angiogenesis 2 . Studies showed that the activity of this agent is mainly limited to those patients whose tumours lack mutations of the RAS genes and cetuximab is currently used for the treatment of RAS wild-type metastatic colorectal cancer [3] [4] [5] .
In contrast with the metastatic setting, cetuximab failed to improve the outcome of patients treated with standard adjuvant chemotherapy 6 and screening for KRAS or RAS mutations did not appear to identify early stage tumours with increased sensitivity to EGFR inhibition 6, 7 . In a recent update of the EXPERT-C trial, we showed a non-significant improvement in survival with cetuximab in both the KRAS/BRAF wild-type and molecularly unselected population 8 . Moreover, in a retrospective biomarker analysis of this study, patients with TP53 wild-type tumours had significantly better survival outcomes when treated with cetuximab and the association between TP53 status and cetuximab benefit was independent of RAS 9 . We hypothesised that antibody-dependent cellular cytotoxicity (ADCC) may have accounted for most of the beneficial effects of cetuximab observed in this trial.
ADCC is an alternative mechanism whereby IgG1 monoclonal antibodies can exert their antitumoural properties 10 . ADCC is initiated when the antigen-binding fragment (Fab) and the crystalline fragment (FC) of the monoclonal antibody engage the tumour cell antigen and a FC gamma receptor (FcγR) on an effector cell, respectively 11 . As a result, antibody-coated tumour cells In this study, we analysed the association bewteen FcγRIIa-FcγRIIIa polymorphisms and cetuximab benefit in a population of high-risk, locally advanced rectal cancer patients treated within the EXPERT-C trial.
Methods
EXPERT-C was an international, multicentre, randomised phase II trial investigating the addition of cetuximab to a sequential treatment strategy with neoadjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy followed by chemoradiotherapy (CRT), total mesorectal excision (TME) and adjuvant CAPOX 18 . Patients were randomised in a 1:1 ratio to receive cetuximab throughout the study treatment or not. Eligibility criteria for EXPERT-C have been described in detail This study was approved by local ethics commmittes and written informed consent was obtained from each patient before study entry.
FcγRIIa and FcγRIIIa polymorphisms analysis
Deoxyribonucleic acid (DNA) was extracted from peripheral blood mononuclear cells (PBMC) 
Tumour molecular analyses
Mutational analyses of KRAS (exons 2-4), NRAS (exons 2-4), and TP53 (exons 4-9) were performed centrally on genomic DNA extracted from formalin-fixed, paraffin-embedded tissue from pretreatment biopsy and/or primary resection samples as previously described 7,9,18 .
Research. (Figure 1 ). Moreover, 131R and 158F alleles carriers were also found to have a lower incidence of distant tumour recurrence at 5 years (21.6% (95% CI: 8.3 -34.9) versus 58% (95% CI: 30.0 -86.1) (HR 0.27, p=0.012) ( Table 3 ).
When we also analysed the outcome of patients treated in the CAPOX control arm according to the FcγRIIa and FcγRIIIa polymorphims, an interaction between cetuximab benefit and presence of 131R and 158F alleles was found for PFS (p=0.017) and distant PFS (p=0.032). After adjusting for prognostic variables including WHO performance status, T4, RAS status, TP53 status and skin rash, this interaction remained significant for both PFS (p=0.003) and distant PFS (p=0.028). An interaction, although not statistically significant, was also observed for OS (p=0.08, adjusted p value 0.09) ( Table 4) .
Tumour mutational status of RAS was available for 98/105 (93.3%) patients. Tumour mutational status of TP53 was available for 94/105 (89.5%) patients. Although further stratification by RAS and TP53 status reduced significantly the number of assessable patients in each group, the beneficial effect of cetuximab in the presence of 131R and 158F alleles did not appear to be significantly influenced by the either RAS or TP53 tumour status (Table 5) .
Discussion
To our knowledge, this is the first study which investigated the potential role of FcγRIIa and FcγRIIIa polymorphisms in predicting cetuximab benefit in the peri-operative setting of colorectal cancer. We showed that, in patients with locally advanced rectal cancer but without radiological evidence of metastatic disease, polymorphic variants of FcγRIIa and FcγRIIIa were associated with increased clinical benefit from cetuximab. In particular, we found that patients carrying 131R and 158F alleles had better survival compared to patients homozygous for the 131H and/or 158V allele advanced disease when compared to patients with early-stage disease or healthy individuals 34, 35 .
Altogether, these data suggest the hypothesis of a dual mechanism of action for cetuximab (i.e.
inhibition of EGFR downstream signalling pathways prevalent for macroscopic tumour lesions and ADCC prevalent for microscopic foci of disease). We acknowledge that our post-hoc, retrospective analysis of a relatively small phase II trial cannot definitively confirm this hypothesis but provides further supportive evidence. Intriguingly, we observed a disconnect between radiologic response of the primary tumour and long-term outcome. Although FcγRIIa-131H and FcγRIIIa-158V
polymorphisms predicted favourable survival outcomes with cetuximab, they did not identify patients with a higher rate of tumour response during preoperative treatment or pathologic complete response at the time of surgery. In contrast, we have previously shown that the mutational status of KRAS (or RAS) maintained its predictive value for response of the primary tumour to cetuximab but did not significantly correlate with the potential, long-term beneficial effect of this drug 7,8 .
Interestingly, and consistently with the hypothesis of ADCC as an important mechanism of action of cetuximab against micrometastases, we found that carriers of 131R and/or 158F alleles had a significantly lower risk of distant failure compared to patients homozygous for 131H and/or 158V when cetuximab was added to the study sequential treatment. It is worth noting that additional signaling pathways beyond EGFR (i.e. IGF-1R pathway) which have been shown to cross-talk with EGFR downstream effectors and mediate the ADCC-independent therapeutic effects of cetuximab are more frequently activated and potentially more clinically relevant in rectal cancer compared to colon cancer [36] [37] [38] . Therefore, our findings could be potentially influenced by the specific location of the primary tumour and may not apply to a population of colon cancer patients.
In order to assess the predictive value of FcγRs polymorphisms independent of the inhibitory effects of cetuximab on the EGFR signalling pathways, we analysed treatment outcomes by RAS status (including KRAS exon 2-4 and NRAS exon 2-4). 
alleles to predict cetuximab benefit was largely independent of the status of RAS. Moreover, and in contrast with our initial hypothesis, the predictive value of these polymorphic variants seemed to be independent of TP53. However, the limited number of patients in these subgroup analyses precludes any definitive conclusion. Larger studies are needed to evaluate the role of ADCC in the adjuvant setting in relation to RAS mutations. Moreover, further investigation is necessary to assess whether enhanced ADCC may be the main mechanism underlying the increased beneficial effects of cetuximab previously observed in patients with TP53 wild-type tumours treated in this trial 9 .
Our has the strongest interaction with IgG and the highest ability to promote the ADCC-related therapeutic response to this agent 39, 40 . However, it is reasonable to argue that, given the interference from several confounding factors including the immune suppression effect of the accompanying chemotherapy agents, the interaction between immune effector cells, monoclonal antibodies and cancer cells in vivo may be by far more complex than that simulated in in vitro conditions 41, 42 .
Moreover, it is worth noting that preclinical studies demonstrated that the different binding affinity of the FcγRIIIa genotypes was maintained at low concentrations but abolished at saturating concentrations of IgG 15, 43 , and the 158F allele was found to be predictive of cetuximab benefit in previous retrospective and prospective series [20] [21] [22] 28 .
For the purpose of this study, a FcγRIIIa-specific primer was used in order to minimise the risk of amplifying FcγRIIIb. Indeed, the high degree of sequence homology between these genes has represented one of the major difficulties in analysing the FcγR polymorphisms and likely one of the most important reasons of the large inconsistency between studies. Importantly, the frequencies of FcγR haplotypes and alleles found in our study population were in line with those described in two large datasets of the Single Nucleotide Polymorphism Database (dbSNP) of the National Center for Biotechnology Information (NCBI) (ss491608261 CSAgilent and ss342007110 ESP cohort populations) 44 and no deviation from the Hardy-Weinberg equilibrium was observed.
We recommend caution in the interpretation of the results of this study which remain hypothesis generating. Moreover, the proposed explanation of our findings is speculative and requires confirmation in future pharmacogenomic studies of cetuximab in a similar patient population.
Indeed, our analysis has several limitations including the retrospective design, the limited number of trial patients eligible for genotyping, the overall small number of patients included in the analysis and the lack of a validation set. Moreover, the inclusion of radiotherapy into the multimodality 
